Novelty:
This technology identifies a form of nitric oxide synthase that may be used as marker of perinatal brain injury. By using an ELISA for this marker, clinicians can evaluate the form of the enzyme – and thereby determine brain injury levels.
Value Proposition:
Current methods to evaluate and measure brain injury incur specificity, accuracy, and time delay issues. The only current method of analyzing and measuring phosphorylation of this enzyme is through the Western blot technique. ELISA has become a reliably powerful method to measure protein phosphorylation, with several advantages over the Western blot. Other advantages of this technology include:
• Ability to accurately predict perinatal brain injury in fetuses
• Possibility to improve infant management to prevent further brain injury
• High specificity and sensitivity due to the use of two antibodies that are target protein specific
• Small sample volumes required to make assessment
Technical Details:
Johns Hopkins researchers have found that the phosphorylated/dephosphorylated status of a neuronal enzyme can be indicative of brain injury. By using an ELISA for this marker, clinicians can evaluate the form and status of the neuronal enzyme –and thereby effectively determine brain injury levels. This technology presents superior diagnostic abilities and quick clinical applications.
Looking for Partners:
To develop and commercialize this technology to provide ELISA assays to determine the status of this particular neuronal enzyme.
Stage of Development:
Preclinical
Publication:
Front. Pediatr. (2017) 5:112.
